

Investor Relations | Hologic

Hologic Receives Health Canada Authorization to Market SculpSure® Laser for Non-Invasive Body Contouring (Lipolysis) of the Back, Inner and Outer Thighs, and Under the Chin



MARLBOROUGH, Mass. May 3, 2018 [/PRNewswire/](#) -- Hologic, Inc. (Nasdaq: HOLX) announced today that it has received a medical device license issued by Health Canada to market Cynosure's advanced non-invasive body contouring product, [SculpSure](#), for treatment of the back, inner and outer thighs, and submental area (under the chin). Unlike other technologies, the SculpSure device uses a laser that raises the temperature of body fat to precisely disrupt and destroy fat cells under the skin to help patients achieve a natural-looking, slimmer appearance. The fat cells are then naturally eliminated by the body over time and do not return.

Importantly, SculpSure laser body treatments (abdomen, flanks, back, inner and outer thigh) are recommended for patients with a body mass index (BMI) of 30 or lower, while SculpSure laser submental treatments (under the chin) have been proven effective on patients with a BMI up to 43. This is a significant advantage over the brand's cryolipolysis competitor, which is only approved to treat patients with a BMI up to 30 in the submental area in the US.

"This authorization is a testament to our commitment to research and meeting the needs of patients," said Kevin Thornal, Divisional President of Cynosure at Hologic. "As a leader in medical aesthetics, we strive to build on our already robust data to secure new indications that provide exceptional efficacy."

The expanded authorizations for back, inner and outer thighs do not require any updates to previously purchased devices. However, the submental treatment requires practitioners to upgrade their SculpSure device and purchase a simple laser attachment, which allows the applicator to fit seamlessly onto the treatment area. Hologic's Cynosure sales force will begin distribution immediately to interested practitioners.

Cynosure, a Hologic company, is a leading developer and manufacturer of a broad array of medical aesthetics systems and technologies. The company has an extensive portfolio of more than 20 products across major categories including body contouring, skin revitalization, women's health and hair removal.

About Hologic, Inc.

Hologic, Inc. is an innovative medical technology company primarily focused on improving women's health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com.

Hologic, The Science of Sure and SculpSure are registered trademarks of Hologic, Inc. in the United States and/or other countries.

Forward-Looking Statements

This news release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic products. There can be no assurance these products will achieve the benefits described herein or that such benefits will be replicated in any particular manner with respect to an individual patient, as the actual effect of the use of the products can only be determined on a case-by-case basis. In addition, there can be no assurance that these products will be commercially successful or achieve any expected level of sales. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such data or statements are based.

Media Contact

Jane Mazur

508.263.8764 (direct)

585.355.5978 (mobile)

jane.mazur@hologic.com

<https://investors.hologic.com/news?item=713>